Anti-VEGF in Real-world

Study Overview
=================
Brief Summary
-----------------
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Detailed Description
-----------------
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Official Title
-----------------
Observation of Anti-vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration, Proliferative Diabetic Retinopathy, Macular Edema, and Choroidal Neovascularization.

Conditions
-----------------
Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy, Retinal Vein Occlusion, Proliferative Diabetic Retinopathy

Intervention / Treatment
-----------------
* Drug: Ranibizumab
* Drug: Aflibercept
* Drug: Conbercept


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with neovascular age-related macular edema (nAMD), diabetic macula edema (DME)/non-proliferative diabetic retinopathy (NPDR)/ proliferative diabetic retinopathy (PDR), retinal vein occlusions related macular edema, and choroidal neovascular (CNV) secondary to multiple retinal diseases. Undergo intravitreal anti-VEGF therapy Exclusion Criteria: unable to receive OCT examination Severe corneal opacity, cataract that affect OCT examination

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neovascular age-related macular edema<br>Patients with new-onset and recurrent Neovascular age-related macular edema. | Drug: Ranibizumab<br>* Ranibizumab 0.5mg/0.05ml intravitreal injection<br>Drug: Aflibercept<br>* Aflibercept 2.0mg/0.05ml intravitreal injection<br>Drug: Conbercept<br>* Conbercept 0.5mg/0.05ml intravitreal injection<br>|
| Diabetic macula edema<br>Patients with new-onset and recurrent diabetic macula edema | Drug: Ranibizumab<br>* Ranibizumab 0.5mg/0.05ml intravitreal injection<br>Drug: Aflibercept<br>* Aflibercept 2.0mg/0.05ml intravitreal injection<br>Drug: Conbercept<br>* Conbercept 0.5mg/0.05ml intravitreal injection<br>|
| Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy<br>Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy | Drug: Ranibizumab<br>* Ranibizumab 0.5mg/0.05ml intravitreal injection<br>Drug: Aflibercept<br>* Aflibercept 2.0mg/0.05ml intravitreal injection<br>Drug: Conbercept<br>* Conbercept 0.5mg/0.05ml intravitreal injection<br>|
| Retinal vein occlusions<br>Patients with new-onset and recurrent retinal vein occlusions | Drug: Ranibizumab<br>* Ranibizumab 0.5mg/0.05ml intravitreal injection<br>|
| Choroidal neovascularization<br>Patients with new-onset and recurrent choroidal neovascularization | Drug: Ranibizumab<br>* Ranibizumab 0.5mg/0.05ml intravitreal injection<br>Drug: Aflibercept<br>* Aflibercept 2.0mg/0.05ml intravitreal injection<br>Drug: Conbercept<br>* Conbercept 0.5mg/0.05ml intravitreal injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity | LogMAR visual acuity | 1 year | 
| Central subfield thickness | he central subfield is defined as the circular area 1 mm in diameter centered around the center point of the fovea | 1 year |